This is not the first time positive safety data has been observed in Covaxin trials. Early reports emerging out of Rohtak, which was selected as a trial centre said that the vaccine was able to elicit safe immunogenicity response and resulted in no considerable side-effects.
Globally, prime vaccine contenders like Oxford University’s candidate, Moderna Inc., CanSino have detailed the existence of certain side-effects in early trials.
Blood samples of the participants have been collected and underwent analysis to study the effects, two weeks apart, as per the dosing schedule. The samples will also be collected on later days (28, 42, 104, 194) for conclusive evidence.